{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-029034","form_type":"8-K","ticker":"ULBI","cik":"0000875657","company_name":"ULTRALIFE CORP","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.213278+00:00","generated_at":"2026-06-09T09:24:51.542367+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultralife Q3 sales $39.5M (+18.8% YoY); operating income $2.1M vs loss","bullets":["GAAP net income $1.3M ($0.08 diluted EPS) vs net loss of $0.2M a year ago.","Adjusted EPS $0.10 vs adjusted loss of $0.03 in Q3 2022.","Gross margin improved 460 bps to 24.8% on price realization and level-loaded production.","Government/defense sales up 48.1%; commercial sales up 5.6%.","Backlog $101.1M at quarter-end, with over $35M expected to ship in remaining 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-029034","json":"https://secwatch.observer/filing/0001437749-23-029034.json","markdown":"https://secwatch.observer/filing/0001437749-23-029034.md","text":"https://secwatch.observer/filing/0001437749-23-029034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875657/000143774923029034/0001437749-23-029034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875657/000143774923029034/ulbi20231025_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:24:51.542367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9c06c4c27f1286bf2c8ed56806a6d240fa5fb4a","claim":"ULTRALIFE CORP reported third quarter ended September 30, 2023 results: revenue $39.5 million, net income $1.3 million or $0.08 per diluted share, EPS $0.08 per diluted share.","evidence_excerpt":"– October 26, 2023 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: ● Sales of $39.5 million representing an 18.8% year-over-year increase ● Operating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarter ● Adjusted EPS of $0.10 compared to a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875657/000143774923029034/0001437749-23-029034-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$39.5 million"},{"label":"Net income","value":"$1.3 million or $0.08 per diluted share"},{"label":"EPS","value":"$0.08 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}